Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Factor IX Double Nickase Plasmid (h): sc-402469-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Factor IX Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Factor IX Double Nickase Plasmid (h) and Factor IX Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting F9. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Factor IX Antibody (B-3): sc-377187
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor IX Double Nickase Plasmid (h) | sc-402469-NIC | 20 µg | $410.00 | |||
Factor IX Double Nickase Plasmid (h2) | sc-402469-NIC-2 | 20 µg | $410.00 |
Human F9 encodes coagulation factor IX, a vitamin K–dependent serine protease zymogen that is activated to factor IXa within the intrinsic pathway of the coagulation cascade. Factor IXa assembles with factor VIIIa, phospholipids, and calcium to form the intrinsic tenase complex, driving factor X activation and downstream thrombin generation. F9 expression and activity are shaped by hepatic synthesis, post-translational γ-carboxylation, and regulated proteolysis that coordinates hemostatic signaling. Genetic or functional perturbation of F9 is strongly associated with hemophilia B and is widely studied as a model for pathway-level control of coagulation protease networks.
Factor IX Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the F9 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within F9. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt F9 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of F9-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.